Roivant Sciences (ROIV) Projected to Post Quarterly Earnings on Thursday

Roivant Sciences (NASDAQ:ROIV) is expected to announce its Q1 2027 results before the market opens on Thursday, August 6th. Analysts expect Roivant Sciences to announce earnings of ($0.33) per share and revenue of $1.9970 million for the quarter. Interested persons can check the company’s upcoming Q1 2027 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Roivant Sciences Stock Down 2.9%

Shares of ROIV stock opened at $32.87 on Thursday. The firm has a 50 day moving average of $32.48 and a 200-day moving average of $28.93. The company has a market cap of $23.64 billion, a price-to-earnings ratio of -54.78 and a beta of 1.11. Roivant Sciences has a 52 week low of $10.90 and a 52 week high of $37.00.

Analysts Set New Price Targets

Several research analysts recently issued reports on ROIV shares. HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Guggenheim increased their price objective on shares of Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Finally, Citigroup raised their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average target price of $33.59.

Insider Buying and Selling at Roivant Sciences

In related news, Director Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the transaction, the director owned 13,701,546 shares of the company’s stock, valued at $473,388,414.30. The trade was a 5.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. This trade represents a 11.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 2,055,913 shares of company stock worth $69,639,633. Insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds have recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV purchased a new position in Roivant Sciences during the fourth quarter worth about $227,000. Sherbrooke Park Advisers LLC purchased a new stake in Roivant Sciences in the 3rd quarter valued at about $221,000. Aptus Capital Advisors LLC bought a new position in shares of Roivant Sciences during the 4th quarter worth approximately $213,000. Guardian Wealth Advisors LLC NC bought a new position in shares of Roivant Sciences during the 4th quarter worth approximately $210,000. Finally, Polen Capital Management LLC purchased a new position in shares of Roivant Sciences in the 4th quarter worth approximately $210,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.